Compare HTT & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
High Templar Tech Limited American depositary shares each representing one Class A ordinary share
Current Price
| Metric | HTT | LYEL |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | 101 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.3M | 401.8M |
| IPO Year | N/A | 2021 |
| Metric | HTT | LYEL |
|---|---|---|
| Price | $2.92 | $12.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 275.5K | 90.6K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8,712.13 |
| P/E Ratio | $4.14 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.88 | $8.49 |
| 52 Week High | $3.91 | $45.00 |
| Indicator | HTT | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 29.46 |
| Support Level | $2.63 | $12.15 |
| Resistance Level | $2.99 | $13.62 |
| Average True Range (ATR) | 0.08 | 1.32 |
| MACD | 0.03 | -0.33 |
| Stochastic Oscillator | 75.26 | 17.78 |
High Templar Tech Ltd is an enabler of financial technology. High Templar is focusing on exploring business opportunities globally to satisfy clients' demand by leveraging its technology know-how and financial service capabilities. The company focus empowering financial institutions with its technological capabilities, helping them improve marketing and operational efficiency and efficiently connect their diverse financial products with online traffic.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.